Literature DB >> 31628529

[New aspects in thyroid cancer treatment : Highlights of the 2019 ASCO Annual Meeting].

N Möckelmann1, C Betz2.   

Abstract

The majority of patients with thyroid cancer have a remarkably good chance of cure in the context of surgical treatment, due to their mostly local tumor spread. However, a small proportion of patients with advanced and metastatic thyroid tumors usually require multimodality treatment. Abstracts from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting are summarized in this review, to provide insights into current aspects of thyroid carcinoma treatment. In addition to innovations in the treatment of radioiodine-refractory differentiated and medullary thyroid carcinoma, current approaches to anaplastic thyroid carcinoma are presented and critically interpreted.

Entities:  

Keywords:  BRAF protein, human; Head and neck neoplasms; Mutation; Protein-tyrosine kinase; RET

Year:  2019        PMID： 31628529     DOI： 10.1007/s00106-019-00764-5

Source DB:  PubMed          Journal:  HNO        ISSN： 0017-6192            Impact factor:   1.284


  11 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors:  Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal:  Lancet       Date:  2014-04-24       Impact factor: 79.321

3.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Authors:  C Durante; N Haddy; E Baudin; S Leboulleux; D Hartl; J P Travagli; B Caillou; M Ricard; J D Lumbroso; F De Vathaire; M Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

4.  Cabozantinib in progressive medullary thyroid cancer.

Authors:  Rossella Elisei; Martin J Schlumberger; Stefan P Müller; Patrick Schöffski; Marcia S Brose; Manisha H Shah; Lisa Licitra; Barbara Jarzab; Viktor Medvedev; Michael C Kreissl; Bruno Niederle; Ezra E W Cohen; Lori J Wirth; Haythem Ali; Colin Hessel; Yifah Yaron; Douglas Ball; Barry Nelkin; Steven I Sherman
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

5.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

6.  A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

Authors:  Maria E Cabanillas; Marcia S Brose; Jaymes Holland; Kimberly C Ferguson; Steven I Sherman
Journal:  Thyroid       Date:  2014-08-27       Impact factor: 6.568

7.  Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer.

Authors:  Mabel Ryder; Ronald A Ghossein; Julio C M Ricarte-Filho; Jeffrey A Knauf; James A Fagin
Journal:  Endocr Relat Cancer       Date:  2008-08-21       Impact factor: 5.678

8.  Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer.

Authors:  Naiyarat Prasongsook; Aditi Kumar; Ashish V Chintakuntlawar; Robert L Foote; Jan Kasperbauer; Julian Molina; Yolanda Garces; Daniel Ma; Michelle A Neben Wittich; Joseph Rubin; Ronald Richardson; John Morris; Ian Hay; Vahab Fatourechi; Bryan McIver; Mabel Ryder; Geoffrey Thompson; Clive Grant; Melanie Richards; Thomas J Sebo; Michael Rivera; Vera Suman; Sarah M Jenkins; Robert C Smallridge; Keith C Bible
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

9.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

Authors:  Samuel A Wells; Bruce G Robinson; Robert F Gagel; Henning Dralle; James A Fagin; Massimo Santoro; Eric Baudin; Rossella Elisei; Barbara Jarzab; James R Vasselli; Jessica Read; Peter Langmuir; Anderson J Ryan; Martin J Schlumberger
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

Review 10.  Clinical Trials in Management of Anaplastic Thyroid Carcinoma; Progressions and Set Backs: A Systematic Review.

Authors:  Behrouz Salehian; Simon Y Liem; Hoda Mojazi Amiri; Ellie Maghami
Journal:  Int J Endocrinol Metab       Date:  2019-01-13
View more
  1 in total

Review 1.  Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.

Authors:  Mian Liu; Pei Chen; Hui-Yu Hu; Deng-Jie Ou-Yang; Rooh-Afza Khushbu; Hai-Long Tan; Peng Huang; Shi Chang
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-02       Impact factor: 4.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.